Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;33(6):1020-1026.
doi: 10.1002/jbmr.3411. Epub 2018 Mar 23.

Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study

Affiliations

Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study

Eugene McCloskey et al. J Bone Miner Res. 2018 Jun.

Abstract

The Screening for Osteoporosis in Older Women for the Prevention of Fracture (SCOOP) study was a community-based screening intervention in women aged 70 to 85 years in the United Kingdom. In the screening arm, licensed osteoporosis treatments were recommended in women identified to be at high risk of hip fracture using the FRAX risk assessment tool (including bone mineral density measurement). In the control arm, standard care was provided. Screening led to a 28% reduction in hip fractures over 5 years. In this planned post hoc analysis, we wished to examine for interactions between screening effectiveness on fracture outcome (any, osteoporotic, and hip fractures) on the one hand and baseline FRAX 10-year probability of hip fracture on the other. All analyses were conducted on an intention-to-treat basis, based on the group to which women were randomized, irrespective of whether screening was completed. Of 12,483 eligible participants, 6233 women were randomized to screening, with treatment recommended in 898 (14.4%). No evidence of an effect or interaction was observed for the outcomes of any fracture or osteoporotic fracture. In the screening arm, 54 fewer hip fractures were observed than in the control arm (164 versus 218, 2.6% versus 3.5%), and commensurate with treatment being targeted to those at highest hip fracture risk, the effect on hip fracture increased with baseline FRAX hip fracture probability (p = 0.021 for interaction); for example, at the 10th percentile of baseline FRAX hip probability (2.6%), there was no evidence that hip fractures were reduced (hazard ratio [HR] = 0.93; 95% confidence interval [CI] 0.71 to 1.23), but at the 90th percentile (16.6%), there was a 33% reduction (HR = 0.67; 95% CI 0.53 to 0.84). Prior fracture and parental history of hip fracture positively influenced screening effectiveness on hip fracture risk. We conclude that women at high risk of hip fracture based on FRAX probability are responsive to appropriate osteoporosis management. © 2018 American Society for Bone and Mineral Research.

Keywords: FRAX; HIP FRACTURE RISK; OSTEOPOROSIS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Observed incidence of osteoporotic and hip fractures during follow‐up in the control arm of the SCOOP study, within quintiles of baseline FRAX hip probability.
Figure 2
Figure 2
Impact of screening on hip fracture compared with control arm, expressed as hazard ratio, across range of FRAX 10‐year hip fracture probabilities at baseline, calculated without BMD. There was evidence of an interaction of effectiveness with baseline probability (p = 0.021). The symbols indicate the range of baseline probabilities in the whole study population (closed symbols) and in the high‐risk group identified by screening (open symbols).

References

    1. Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016; 11(1):25. - PMC - PubMed
    1. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19(4):385–97. - PMC - PubMed
    1. Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017; 12(1):43. - PMC - PubMed
    1. McCloskey EV, Johansson H, Oden A, et al. The effect of abaloparatide‐SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study. J Bone Miner Res. 2017; 32(8):1625–31. - PMC - PubMed
    1. Harvey NC, Kanis JA, Oden A, et al. FRAX and the effect of teriparatide on vertebral and non‐vertebral fracture. Osteoporos Int. 2015; 26(11):2677–84. - PMC - PubMed

Publication types